Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
Public ClinicalTrials.gov record NCT03237065. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-label, Comparative Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside/Ferric Derisomaltose and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia (Phosphare-IDA-05)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The trial was designed to evaluate the incidence of unintended hypophosphatemia (low level of phosphate in the blood) in subjects with iron deficiency anaemia (IDA).
Study identification
- NCT ID
- NCT03237065
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 122 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 30, 2017 (Actual)
- Primary completion
- May 29, 2018 (Actual)
- Completion
- May 29, 2018 (Actual)
- Last update posted
- Feb 25, 2020
2017 – 2018
United States locations
- U.S. sites
- 15
- U.S. states
- 9
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pharmacosmos Investigational Site | Muscle Shoals | Alabama | 35661 | — |
| Pharmacosmos Investigational Site | Doral | Florida | 33122 | — |
| Pharmacosmos Investigational Site | Miami | Florida | 33144 | — |
| Pharmacosmos Investigational Site | Miami | Florida | 33165 | — |
| Pharmacosmos Investigational Site | Miami Lakes | Florida | 33014 | — |
| Pharmacosmos Investigational Site | Orlando | Florida | 32819 | — |
| Pharmacosmos Investigational Site | Idaho Falls | Idaho | 83404 | — |
| Pharmacosmos Investigational Site | Oak Brook | Illinois | 60523 | — |
| Pharmacosmos investigational Site | Flint | Michigan | 48504 | — |
| Pharmacosmos Investigational Site | St Louis | Missouri | 63119 | — |
| Pharmacosmos Investigational Site | Las Vegas | Nevada | 89146 | — |
| Pharmacosmos Investigational Site | Albuquerque | New Mexico | 87102 | — |
| Pharmacosmos Investigational Site | Morehead City | North Carolina | 28557 | — |
| Pharmacosmos Investigational Site | Raleigh | North Carolina | 27607 | — |
| Pharmacosmos Investigational Site | Winston-Salem | North Carolina | 27103 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03237065, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 25, 2020 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03237065 live on ClinicalTrials.gov.